Drug Approval | August 24, 2022
Merck gets fast track designation from the USFDA for anticoagulant therapy
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
Company raises the annual revenue guidance from mid-teens to high teens
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Syngene's collaboration with Zoetis started in 2011
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Innate to receive $5M milestone payment from AstraZeneca
The drug will be available in 600 hospitals and 105 DTPs
The inspection report contains no 'critical' observations and only one of the deficiencies is categorized as 'major' which is being addressed expeditiously in consultation with the regulatory agency
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
